TURNING POINT THERAPEUTICS
Turning Point Medicines for Life!
About
Turning Point Therapeutics, Inc. is a clinical-stage structure-based drug design company for the discovery and development of precision medicines for cancer and other diseases. We are focusing on the design of novel chemical identities for established oncogene drivers with secondary resistant mutations, newly identified disease-driven targets, and potential targets regulating tumor microenvironment and tumor immunity. Our lead therapeutic project, TPX-0005 (Repotrectinib), is in clinical development (TRIDENT-1).
Leadership
Link to: J. Jean Cui, Ph.D.
J. Jean Cui, Ph.D.
Scientific Founder, Chairman, and Chief Scientific Officer
Link to: Robert Xin, M.D., Ph.D.
Robert Xin, M.D., Ph.D.
Senior Vice President of Clinical Development
Link to: Armin Graber, Ph.D.
Armin Graber, Ph.D.
Vice President of Companion Diagnostics & Biomarkers
Link to: Naresh K. Nayyar, Ph.D., M.B.A., RAC
Naresh K. Nayyar, Ph.D., M.B.A., RAC
Vice President of Regulatory Affairs
Link to: Jeffrey P. Whitten, Ph.D., M.B.A.
Jeffrey P. Whitten, Ph.D., M.B.A.
Senior Vice President of Pre-Clinical Development
Link to: Yishan (Peter) Li, Ph.D., M.B.A.
Yishan (Peter) Li, Ph.D., M.B.A.
Co-Founder, Director, and Head of Turning Point Therapeutics Asia
Board of Directors
Link to: J. Jean Cui, Ph.D.
J. Jean Cui, Ph.D.
Scientific Founder, Chairman, and Chief Scientific Officer
Link to: Yishan (Peter) Li, Ph.D., M.B.A.
Yishan (Peter) Li, Ph.D., M.B.A.
Co-Founder, Head of Turning Point Therapeutics Asia
Scientific Advisory Board
What is Precision Medicine?
Precision medicine takes into account the precise information about the variability of each individual’s genes, proteins, environment and life style for the prevention, diagnosis, and treatment of human diseases. The human body consists of about 37 trillion living cells, each containing about 23,000 genes. No two humans are genetically identical. Even monozygotic twins have genetic differences due to mutations, genetic rearrangements and polymorphisms during development. As we uncover the mechanism on how the genome affects health, disease, and response to drugs, it becomes clear that we must take into account individual differences in each person’s genes, environment and lifestyle for better disease prevention and treatment. Most of current medical treatments have been designed for the “average patient”. This “one-size-fits-all” approach inevitably leads to successful treatments for some patients but not for others. Precision medicine, also known as personalized medicine, was proposed to fill in the gap. The advancements in genomic sequencing technology and rapid reduction in sequencing cost are leading to widespread utilization of patient genomic information and paving the way for a new era of precision medicine. The Precision Medicine Initiative launched by President Obama in his State of Union Address in January 2015 provides another significant push in facilitating research, development, innovation as well as regulatory modernization for precision medicine.
The paradigm of cancer treatment has already shifted toward precision oncology. Patients are selected for therapy using predictive biomarkers, such as oncogenic mutations, rather than using empiric chemotherapy. Currently, patients with breast cancer, lung cancer, colorectal cancer, melanoma, and leukemia routinely undergo molecular diagnostic testing as part of patient care, enabling doctors to choose more precise treatments that improve chances of survival and reduce adverse effects. High-throughput genomic technologies and programmatic sequencing efforts, such as NCI/ National Human Genome Research Institute Cancer Genome Atlas Network, and the Sanger Cancer Genome Project have generated the molecular profiles of numerous cancers, and identified actionable targets for therapeutic intervention. Targeting the oncogenic driver mutations has been a proven effective therapeutic strategy to control tumor growth and disease progression. Trastuzumab (Herceptin®), the first genotype-guided therapy for the treatment of HER-2 positive metastatic breast cancers was approved in 1998. Identification of the causative genetic lesion BCL-ABL in chronic myelogenous leukemia (CML) resulted in the breakthrough medicine imatinib (Gleevec®), a tyrosine kinase ABL inhibitor for the treatment of CML in 2001. Cancer patients and oncology community expect to see many more discoveries leading to novel treatments for the unmet medical needs. With in-depth knowledge, enriched experience and successful track record in the marketed precision oncology medicines (XALKORI® and SUTENT®), our TP Therapeutics (TP) discovery and development team led by Dr. J. Jean Cui are well-positioned to discover and develop more effective targeted therapy drugs and make significant contributions in the new Era of Precision Medicine.
Pipeline
Turning Point Therapeutics’ pipeline includes potent inhibitors targeting established oncogene drivers, and the acquired resistance (including secondary resistant mutations, bypass mechanisms, and epithelial–mesenchymal transition) that develop from today’s current available therapies. Our team is also working on newly identified novel disease-driven targets, and targets regulating the tumor microenvironment and tumor immunity.
TPX-0005 (Repotrectinib)
Turning Point Therapeutics is presently conducting a Phase 1/2 clinical trial with our Investigational Drug, TPX-0005 (Repotrectinib). This study is currently enrolling patients in the US and South Korea. More information about this study is available from www.clinicaltrials.gov. Patients and healthcare providers may also contact the Turning Point Therapeutics Clinical Team about clinical trials in oncology at (858) 276-0005, or by email at clinical@tptherapeutics.com.
TPX-0005 (Repotrectinib) was designed to target the oncogenic fusion genes of NTRK family, ROS1, and ALK that are present in certain cancers. With the advances in precision medicine, it is now possible for healthcare providers to test the abnormal genes in tumors and select a specific treatment based on the test results. The tyrosine kinase inhibitors targeting TRK family (TRKA, TRKB, and TRKC), ROS1, and ALK fusion protein have demonstrated great effectiveness in shrinking tumor or control the tumor growth in clinic. Nevertheless, there have been more and more cases of drug resistance after certain period of treatment. Turning Point Therapeutics’ drug, TPX-0005 (Repotrectinib), was created not only targeting the primary tumors with NTRK, ROS1 or ALK abnormal gene, but also the resistant tumors developed from tyrosine kinase inhibitor treatment. Therefore, TPX-0005 (Repotrectinib) could be suitable for treating cancer patients with abnormal gene of NTRK, ROS1 or ALK including with resistance mutations.
The suitable cancers may include:
Non-Small Cell Lung Cancer (NSCLC), Colorectal adenocarcinoma, Mammary Analogue of Secretory Carcinoma (MASC) of the salivary gland, Squamous cell head and neck cancer, Spitzoid melanoma, Gastrontestinal Stromal Tumor (GIST), Cholangiocarcinoma, Soft tissue sarcoma, Inflammatory Myofibroblastic Tumor (IMT), Soft tissue fibrosarcoma (pediatric), Soft tissue fibrosarcoma (pediatric), Soft tissue schwannoma (pediatric), Soft tissue hemangioma (pediatric), Soft tissue solitary fibrous tumor (pediatric), Infantile (congenital) fibrosarcoma, Glioblastoma Multiforme (GBM), Low grade glioma, Pediatric non-brainstem high grade glioma, Papillary thyroid, and Secretory breast carcinoma, Pigmented spindle cell nevus/Spitz nevus, Bladder cancer, Breast cancer, Rectal adenocarcinoma, Renal carcinoma, Renal medullary carcinoma, Thyroid cancer (anaplastic) and Thyroid cancer (medullary).
TPX-0005 (Repotrectinib) could be used for treating resistant patients developed from the treatment(s) of:
- TRK inhibitors: larotrectinib, entrectinib, LOXO-195 and others;
- ROS1 inhibitors: crizotinib, lorlatinib, entrectinib, ceritinib, and others;
- ALK inhibitors: crizotinib, ceritinib, alectinib, brigatinib, lorlatinib, ensartinib, entrectinib, and others.
Press Releases
Publications & Posters
Career Openings
Thank you for your interest in Turning Point Therapeutics. Turning Point is a clinical-stage structure-based drug design company for the discovery and development of precision medicines for cancer and other diseases. We are focusing on the design of novel chemical identities for established oncogene drivers with secondary resistant mutations, newly identified disease-driven targets, and potential targets regulating tumor microenvironment and tumor immunity.
Contact
Turning Point Therapeutics, Inc.
10628 Science Center Drive, Ste. 225
San Diego, CA 92121
For General Inquiry:
(858) 926-5251
For Inquiry on TPX-0005 (Repotrectinib) Clinical Trial:
(858) 276-0005